Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study

Purpose To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. Methods Outcomes were investigated according to overall fluid status at week 16 (predef...
Ausführliche Beschreibung

Purpose To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. Methods Outcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 96 (post-hoc). The analyses involved treatment-naïve patients (N = 246) with exudative age-related macular degeneration (AMD), aged ≥ 50 years with BCVA of 73–25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study. Results The mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% (week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% (SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF. Conclusion IVT-AFL T&E dosing was effective at clearing fluid regardless of fluid type in ~ 80% of patients with exudative AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with < 20% of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated with poorer BCVA, whereas SRF was not. Trial registration ClinicalTrials.gov Identifier: NCT02305238 Ausführliche Beschreibung

Autor*in:	Ohji, Masahito [verfasserIn] Okada, Annabelle A. Sasaki, Koji Moon, SungChul Charles Machewitz, Tobias Takahashi, Kanji

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Aflibercept Exudative age-related macular degeneration Ophthalmology Treat-and-extend Post-hoc

Anmerkung:	© The Author(s) 2021. corrected publication 2022

Übergeordnetes Werk:	Enthalten in: Graefe's archive for clinical and experimental ophthalmology - Berlin : Springer, 1854, 259(2021), 12 vom: 20. Juli, Seite 3637-3647
Übergeordnetes Werk:	volume:259 ; year:2021 ; number:12 ; day:20 ; month:07 ; pages:3637-3647

Links:	Volltext

DOI / URN:	10.1007/s00417-021-05293-y

Katalog-ID:	SPR045549710